home / stock / nvsef / nvsef news


NVSEF News and Press, Novartis Ag Basel Akt From 02/12/24

Stock Information

Company Name: Novartis Ag Basel Akt
Stock Symbol: NVSEF
Market: OTC
Website: novartis.com

Menu

NVSEF NVSEF Quote NVSEF Short NVSEF News NVSEF Articles NVSEF Message Board
Get NVSEF Alerts

News, Short Squeeze, Breakout and More Instantly...

NVSEF - Federal judge dismisses PhRMA challenge to Medicare price negotiations

2024-02-12 21:01:27 ET More on Bristol-Myers Squibb Company , Eli Lilly, etc. Pfizer Stock: It's Time To Buy The Dip Pfizer Is A Great Investment Over The Next Decade; Buy Will Eli Lilly and Company Become A Trillion-Dollar Baby? RayzeBio ticks higher af...

NVSEF - Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

2024-02-11 04:27:27 ET Summary Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-relat...

NVSEF - Mineralys: 2nd Half 2024 Hypertension Data Readout

2024-02-09 09:33:11 ET Summary Mineralys Therapeutics, Inc. has two ongoing studies evaluating use of lorundrostat for the treatment of patients with uncontrolled or resistant hypertension; these are ADVANCE-HTN and LAUNCH-HTN. Results from the phase 3 ADVANCE-HTN study using loru...

NVSEF - U.S. govt. sends opening bids for drugs selected for Medicare price negotiations

2024-02-01 10:13:39 ET More on Bristol-Myers, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree Wit...

NVSEF - U.S. govt. sends opening bids for drugs selected for Medicare pricing negotiations

2024-02-01 10:13:39 ET More on Bristol-Myers Squibb, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disag...

NVSEF - Novartis AG (NVS) Q4 2023 Earnings Call Transcript

2024-01-31 12:39:03 ET Novartis AG (NVS) Q4 2023 Earnings Conference Call January 31, 2024 08:00 AM ET Company Participants Samir Shah - Global Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Confer...

NVSEF - Legend Biotech: Solid Traction With Carvykti Rollout

2024-01-29 13:47:30 ET Summary Today, we take a look at Legend Biotech Corporation, a commercial-stage biopharmaceutical company focused on developing cell therapies for oncology and other indications. The company has one approved product on the market, LCAR-B38M, for the treatmen...

NVSEF - PBMs ramp up lobbying efforts amid growing public scrutiny

2024-01-26 07:16:34 ET More on Cigna, CVS Health, etc. Humana: The $300 Level Could Get Taken Out In The Near Future Humana Inc. (HUM) Q4 2023 Earnings Call Transcript CVS Health: Back In The Buy Column Humana gets downgrade at Deutsche Bank as stock nears fo...

NVSEF - Polaris International Equity Composite Q4 2023 Commentary

2024-01-19 01:30:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

NVSEF - Polaris Global Equity Composite Q4 2023 Commentary

2024-01-18 11:00:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

Previous 10 Next 10